HMB-002, an antibody-based experimental treatment for von Willebrand disease (VWD) currently in early clinical testing, boosted levels of the protein whose deficiency causes VWD,…
Adults with immune thrombocytopenia (ITP) may be at risk of developing blood clots, and prompt control of the disease may help anticoagulation (blood thinners) be started when needed, with long-term treatment considered for patients who remain at high risk, a French study found. The study, “Incidence, Characteristics, and…
Latest news & perspectives
Following rituximab treatment, people of African ancestry with immune thrombotic thrombocytopenic purpura (iTTP) experience a relapse significantly sooner than individuals with European ancestry, a…
